Where does treatment fit into the strategy to control hepatitis C?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue SUPPL. MAY, 2000, Pages

  Desmond, Paul ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS VACCINE; INTERFERON; RIBAVIRIN;

ASIA; CLINICAL TRIAL; CONFERENCE PAPER; HEALTH CARE COST; HEALTH PROMOTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; LIVER CIRRHOSIS; LIVER FIBROSIS; PACIFIC ISLANDS; PREVALENCE; PRIORITY JOURNAL; SEXUAL TRANSMISSION; VERTICAL TRANSMISSION;

EID: 0033932435     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02107.x     Document Type: Conference Paper

References (17)

1. Abrignani S, Rosa D. Perspectives for a hepatitis C virus vaccine. Clin. Diagn.Virol. 1998; 10: 181-5.
2. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: S62-5.
3. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 1999; 341: 556-62.
4. Crofts N, Aitken CK, Kaldor JM. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med. J. Aust. 1999; 170: 220-1.
5. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29: 1596-601.
6. Mather D, Crofts N. A computer model of the spread of hepatitis C virus among injecting drug users. Eur. J. Epidemiol. 1999; 15: 5-10.
7. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group [See Comments]. N. Engl. J. Med. 1998; 339: 1485-92.
8. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C [In Process Citation]. Semin. Liver Dis. 1999; 19 (Suppl. 1): 57-65.
9. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27: 1730-5.
10. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: The OBSVIRC, METAVIR, CLINIVIR, DOSVIRC Groups. Lancet 1997; 349: 825-32.
11. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus: International Hepatitis Interventional Therapy Group (IHIT) [see Comments]. Lancet 1998; 352: 1426-32.
12. Poynard T, Opolon P. Hepatitis C: somber views of natural history and optimistic views of interferon treatment? [Editorial & Comment] Hepatology 1998; 27: 1443-4.
13. Randal J. Hepatitis C vaccine hampered by viral complexity, many technical restraints [News]. J. Natl. Cancer Inst. 1999; 91: 906-8.
14. Schalm SW, Weiland O, Hansen BE et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 1999; 117: 408-13.
15. Sobesky R, Mathurin P, Charlotte F et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C. a dynamic view: The Multivirc Group. Gastroenterology 1999; 116: 378-86.
16. Strasser SI, Watson KJ, Lee CS, Coghlan PJ, Desmond PV. Risk factors and predictors of outcome in an Australian cohort with hepatitis C virus infection [see Comments]. Med. J. Aust. 1995; 162: 355-8.
17. Thompson SC, Ogilvie EL, Veit FC, Crofts N. Juvenile offenders and hepatitis B. risk, vaccine uptake and vaccination status. Med. J. Aust. 1998; 169: 306-9.